Sinaptica Therapeutics received both the Judge’s Award and People’s Choice Award at the 2024 Capital & Growth Pitch Sessions.
Their personalized, non-invasive brain stimulation is showing an 82% reduction in Alzheimer’s progression at 6 months—with effects lasting up to a year. A breakthrough approach that’s far exceeding the efficacy of current treatments.
Why Present at OMIF 2026?
- VISIBILITY
Gain unparalleled exposure among industry leaders, investors, and medtech professionals. - NETWORKING
Connect with potential collaborators, investors, and key decision-makers in the medtech space. - SHOWCASE YOUR IMPACT
Demonstrate how your company is shaping the future of medical innovation through cutting-edge technologies.
Apply to Pitch at Octane's Medical innovation Forum 2026
The session will feature the top 20 carefully selected and curated companies that will pitch for capital to our strategics including our longstanding partners such as Edwards Lifesciences, AbbVie, and Medtronic, as well as industry experts, hospital systems including Hoag, City of Hope, UCI Health and CHOC, and investors.
Octane will be presenting two awards: the People’s Choice Award and the Judge’s Choice Award.
Pitch your company to Octane’s ecosystem of high net worth angel investors and angel groups, family office, venture capitalists, strategics, and industry leaders.
Aruna Revolution was honored with both the Judge’s Award and People’s Choice Award at the 2024 Capital & Growth Pitch Sessions.
Their compostable menstrual products offer a safe, sustainable solution for personal and environmental health—breaking down into soil-enriching materials while reducing waste and impact.
2026 Presenting Companies
LensPLus
Plasma surface-treatment platform for contact lens manufacturers that fixes poor wettability, the #1 cause of discomfort and dropout that easily can be implemented on existing production lines,
Pnemua Therapeutics
xchange is a 510(k)-cleared perioperative airway stabilization system for anesthesiologists and CRNAs to rapidly prevent and reverse oxygen desaturation during moderate to deep sedation, especially in high-risk patients.